Hanmi Pharm and Celltrion are showing strength in the early market on the 21st on news of the production of an edible treatment for COVID-19.
On the stock market at 9:08 am on the same day, Hanmi Pharm was trading at 266,500 won, up 3.09% from the previous trading day, and Celltrion at 166,000 won, up 0.61%.
On the previous day, the Ministry of Health and Welfare, Hanmi Pharm, Celltrion, and Dongbang FTL, produced 105 medium-to-low-priced drugs (generic drugs) of Molnupiravir (product name ‘Lagebrio’), an oral treatment for COVID-19 developed by Merck & Company (MSD). It is said that it will supply to income countries.
Pfizer’s selection of a generic drug manufacturer for Paxrovid, an oral treatment drug, is under review.
/yunhap news
ⓒ Hankyung.com, unauthorized reprinting and redistribution prohibited
